Preclinical Isolated Organ Perfusion System Market is estimated to be valued at USD 566.8 Mn in 2026 and is expected to reach USD 754.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 566.8 Mn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
4.10% |
2033 Value Projection: |
USD 754.0 Mn |
Isolated organ perfusion is an excellent tool for investigating the physiology and function of a variety of individual organs. It enables exploration of organs and their pharmacologic reactions. Isolated perfusion helps to understand the hemodynamics, effects of various perfusates, and toxicity of drugs on individual organs.
Market Dynamics
An increasing number of organ transplants is expected to drive the global preclinical isolated organ perfusion system market growth. For instance, according to an article published by the United Network for Organ Sharing, a non-profit, scientific and educational organization, in 2016, 33,600 organ transplants were performed in the U.S. and 114,756 patients were on the waiting list.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global preclinical isolated organ perfusion system market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are World Precision Instruments Inc., Radnoti LLC, MDE GmbH, Harvard Bioscience Inc., emka TECHNOLOGIES S.A.S., Danish Myo Technology AS, ADInstruments Pty Ltd. and Experimetria Ltd. among others.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global preclinical isolated organ perfusion system market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preclinical isolated organ perfusion system market.
Market Segmentation
- By Type (Revenue, USD Mn, 2021-2033)
- Isolated Heart Perfusion Systems
- Isolated Abdominal Organ Perfusion Systems
- Isolated Lung Perfusion Systems
- Others
- By Application (Revenue, USD Mn, 2021-2033)
- Industrial Laboratories and CROs
- Academic and Government Research Institutes
- By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Competitive Landscape
- World Precision Instruments Inc.
- Radnoti LLC
- MDE GmbH
- Harvard Bioscience Inc.
- emka TECHNOLOGIES S.A.S.
- Danish Myo Technology AS
- ADInstruments Pty Ltd.
- Experimetria Ltd.